RHINOCEREBRAL MUCORMYCOSIS: A CASE REPORT

Authors

  • Ermias Shenkutie Greffie University of Gondar
  • Zenahbizu Abay University of Gondar
  • Habtewold Shibiru University of Gondar

Abstract

Rhinocerebral mucormycosis is an uncommon and deadly acute necrotizing fungal infection. It usually affects individuals with underlying immunosuppression with uncontrolled diabetes and diabetic ketoacidosis being the most commonly identified condition. High index of suspicion is crucial for early diagnosis and management as it is a rapidly progressive infection with high rate of fatality. In this case report, we present an 18 years old female patient with type 1 diabetes mellitus, diabetic ketoacidosis and confirmed rhinocerebral mucormycosis from University of Gondar Hospital. The clinical presentation, diagnostics and hospital course is discussed.

Author Biographies

Ermias Shenkutie Greffie, University of Gondar

Assistant professor of Internal Medicine

Zenahbizu Abay, University of Gondar

Assitant Professor of Internal Medicine

Habtewold Shibiru, University of Gondar

Senior Resident, Internal Medicine

References

Mallis A, Mastronikolis S, Naxakis S, Papadas A. Rhinocerebral mucormycosis: an update. Eur Rev Med Pharmacol Sci. 2010;14(11):987-92.

Wadhawan R, LuthraK YR, Solanki G. Mucormycosis; deadlier infection: an overview. ActaBiomedicaScientia. 2015;2(1):11-5.

Mohamed MS, Abdel-Motaleb HY, Mobarak FA. Management of rhino-orbital mucormycosis. Saudi medical journal. 2015;36(7):865.

Bitar D, Van Cauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006. Emerg Infect Dis. 2009;15(9):1395-401.

Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clinical Infectious Diseases. 2005;41(5):634-53.

Spellberg B, Edwards J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clinical Microbiology Reviews. 2005;18(3):556-69.

Kolekar JS. Rhinocerebral mucormycosis: a retrospective study. Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India. 2015;67(1):93-6. Epub 2015/01/27.

Goldstein EJ, Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clinical Infectious Diseases. 2009;48(12):1743-51.

Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny MI, French SW, et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. The Journal of clinical investigation. 2007;117(9):2649-57. Epub 2007/09/06.

Reed C, Ibrahim A, Edwards JE, Walot I, Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrobial agents and chemotherapy. 2006;50(11):3968-9.

Kajs-Wyllie M. Hyperbaric oxygen therapy for rhinocerebral fungal infection. Journal of Neuroscience Nursing. 1995;27(3):174-81.

Downloads

Published

2017-06-28

Issue

Section

Case Report